HER2 Antibodies

Global HER2 Antibodies Market to Reach US$31.3 Billion by 2030

The global market for HER2 Antibodies estimated at US$20.5 Billion in the year 2024, is expected to reach US$31.3 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Trastuzumab, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$20.5 Billion by the end of the analysis period. Growth in the Lapatinib segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.7 Billion While China is Forecast to Grow at 6.6% CAGR

The HER2 Antibodies market in the U.S. is estimated at US$5.7 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global HER2 Antibodies Market - Key Trends & Drivers Summarized

Why Are HER2 Antibodies Essential In The Treatment Of Breast Cancer?

HER2 antibodies are crucial in the treatment of HER2-positive breast cancer, which is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. HER2-positive breast cancer tends to be more aggressive and has a higher likelihood of recurrence compared to HER2-negative types. HER2 antibodies, such as trastuzumab, pertuzumab, and newer biosimilars, target the HER2 protein on cancer cells, inhibiting cell proliferation and inducing immune-mediated cell death. These targeted therapies have revolutionized breast cancer treatment, significantly improving survival rates and quality of life for patients. As awareness of HER2-targeted therapies increases and diagnostic tools improve, the demand for HER2 antibodies is expected to grow further.

What Innovations Are Driving The HER2 Antibodies Market?

Innovations in biologic drug development and targeted therapy are significantly driving the HER2 antibodies market. The development of next-generation HER2 antibodies, such as antibody-drug conjugates (ADCs) and bispecific antibodies, is providing more effective treatment options with fewer side effects. ADCs, like ado-trastuzumab emtansine (T-DM1), combine HER2-targeting antibodies with cytotoxic agents, delivering targeted cell killing while minimizing damage to healthy cells. Furthermore, advancements in biosimilar development are making HER2 therapies more accessible and affordable, expanding their availability to a broader patient population. These innovations, coupled with personalized medicine approaches that use biomarkers for patient selection and treatment optimization, are enhancing the therapeutic landscape of HER2-positive breast cancer.

How Are Market Dynamics And Regulatory Factors Shaping The HER2 Antibodies Market?

Market dynamics, such as the rising incidence of HER2-positive breast cancer and increasing awareness of targeted therapies, are significantly shaping the HER2 antibodies market. Regulatory factors, including expedited approvals for breakthrough therapies and biosimilars by agencies like the FDA and EMA, are promoting innovation and competition in the market. The growing focus on reducing healthcare costs is also driving the adoption of biosimilars, which offer cost-effective alternatives to branded HER2 antibodies. Additionally, advancements in diagnostic tools and screening programs are facilitating early detection and treatment of HER2-positive breast cancer, further supporting market growth.

What Factors Are Driving The Growth Of The HER2 Antibodies Market?

The growth in the HER2 antibodies market is driven by several factors, including the rising prevalence of HER2-positive breast cancer, advancements in biologic drug development, and supportive regulatory frameworks. A key driver is the increasing demand for targeted therapies that offer improved efficacy and safety profiles compared to traditional chemotherapy. The development of next-generation HER2 antibodies, biosimilars, and combination therapies is also expanding treatment options and enhancing patient outcomes. Additionally, the expansion of cancer screening programs and the availability of companion diagnostics are supporting early diagnosis and personalized treatment approaches. These factors, coupled with ongoing innovations in oncology research and targeted therapy, are driving the global HER2 antibodies market forward.

SCOPE OF STUDY:

The report analyzes the HER2 Antibodies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Segment (Trastuzumab, Lapatinib, Ado-Trastuzumab Emtansine, Pertuzumab, Everolimus)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 47 Featured) -

• Abnova Corporation
• Biocon Ltd.
• Bio-Techne Coporation
• Celltrion, Inc.
• Genentech, Inc.
• Invivogen
• Novartis AG
• Pfizer, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.